Publications by authors named "Neil Leatherbury"
Article Synopsis
- mRNA therapies have become popular, especially after the approval of mRNA vaccines against SARS-CoV-2, but large-scale production faces significant challenges.
- The production process can be inefficient and costly due to issues with incorporating necessary cap analogs and the creation of unwanted double-stranded RNA byproducts that can trigger immune reactions.
- Researchers have developed a new RNA polymerase called T7-68 that improves the incorporation of cap analogs and reduces the presence of harmful dsRNA, enhancing the efficiency of mRNA production.
Persistence of chronic hepatitis B (CHB) is attributed to maintenance of the intrahepatic pool of the viral covalently closed circular DNA (cccDNA), which serves as the transcriptional template for all viral gene products required for replication. Current nucleos(t)ide therapies for CHB prevent virus production and spread but have no direct impact on cccDNA or expression of viral genes. We describe a potential curative approach using a highly specific engineered ARCUS nuclease (ARCUS-POL) targeting the hepatitis B virus (HBV) genome.
View Article and Find Full Text PDFMRX34, a microRNA (miRNA)-based therapy for cancer, has recently entered clinical trials as the first clinical candidate in its class. It is a liposomal nanoparticle loaded with a synthetic mimic of the tumor suppressor miRNA miR-34a as the active pharmaceutical ingredient. To understand the pharmacokinetic properties of the drug and to rationalize an optimal dosing regimen in the clinic, a method is needed to quantitatively detect the miRNA mimic.
View Article and Find Full Text PDF